Skip to main content

AbbVie Inc. Venclexta revenue

  • ABBV · NYSE
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$295.03+0.20%Close 13 Nov 2026 · Market value $524.5B

Venclexta revenue at AbbVie Inc. came to $803.0M for the quarter to 30 Sep 2026, up 10.6% from a year earlier.

As AbbVie Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.

By quarter

$589.0MDec 2023$614.0MMar 2024$637.0MJun 2024$677.0MSep 2024$655.0MDec 2024$665.0MMar 2025$691.0MJun 2025$726.0MSep 2025$710.0MDec 2025$770.0MMar 2026$771.0MJun 2026$803.0MSep 2026
AbbVie Inc. Venclexta revenue, every reported period
Period endingVenclexta revenueChange on a yearFiled
30 Sep 2026$803.0Mup 10.6%30 Oct 2026
30 Jun 2026$771.0Mup 11.6%31 Jul 2026
31 Mar 2026$770.0Mup 15.8%29 Apr 2026
31 Dec 2025$710.0Mup 8.4%4 Feb 2026
30 Sep 2025$726.0Mup 7.2%31 Oct 2025
30 Jun 2025$691.0Mup 8.5%31 Jul 2025
31 Mar 2025$665.0Mup 8.3%25 Apr 2025
31 Dec 2024$655.0Mup 11.2%31 Jan 2025
30 Sep 2024$677.0Mup 14.7%30 Oct 2024
30 Jun 2024$637.0M—25 Jul 2024
31 Mar 2024$614.0M—26 Apr 2024
31 Dec 2023$589.0M—2 Feb 2024
30 Sep 2023$590.0M—27 Oct 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of AbbVie Inc.: Skyrizi revenue · Rinvoq revenue · Botox Therapeutic revenue · Vraylar revenue · Humira revenue · Botox Cosmetic revenue · Imbruvica revenue · Ubrelvy revenue · Qulipta revenue · Creon revenue · Vyalev revenue · Mavyret revenue · Elahere revenue · Juvederm Collection revenue · Linzess/Constella revenue · Ozurdex revenue · Epkinly revenue · Lumigan/Ganfort revenue · Duodopa revenue · Alphagan/Combigan revenue · Immunology revenue · Neuroscience revenue · Oncology revenue · Aesthetics revenue · financial statements

Every KPI and segment of ABBV, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.